Erica Barnell
@EricaBarnell
Followers
314
Following
1K
Media
25
Statuses
249
MD/PhD | Geneoscopy CMO/CSO | Forbes 30 Under 30
St Louis, MO
Joined February 2018
RT @GeneoscopyCo: FOR IMMEDIATE RELEASE:.Geneoscopy Sibling Co-founders Named Finalists for EY Entrepreneur Of The Year 2025 Heartland Awar….
0
6
0
RT @GeneoscopyCo: FOR IMMEDIATE RELEASE: Geneoscopy secures $105M Series C funding led by @BioRad to launch ColoSense®, a non-invasive colo….
0
1
0
RT @GeneoscopyCo: Digestive Disease Week 2024 provided an excellent opportunity to showcase Geneoscopy's RNA technology and connect with ot….
0
3
0
RT @P_DeepakIBDMD: 🤩 Day 1 @DDWMeeting for our team across topics:.- Single cell analyses/spatial transcriptomics in perianal Crohn’s & Cro….
0
9
0
RT @DaveMessina: Incredible work by @EricaBarnell, Andrew Barnell, and the whole @GeneoscopyCo team. I've had the opportunity to watch the….
0
2
0
RT @GeneoscopyCo: Geneoscopy is thrilled to announce the FDA approval of #ColoSense, our noninvasive multi-target stool RNA-based #Colorect….
0
9
0
After being a student at @WUSTLmed for nearly a decade, it is an honor to be highlighted as an alumna by the Washington Magazine.
source.washu.edu
Erica Barnell co-founded the life sciences company Geneoscopy to develop innovative diagnostics and transform gastrointestinal health.
0
0
12
RT @ARosen380: Great session at @AACR on advancement in colorectal cancer screening tests! These experts @drfolamay @IssakaMD & @samirgupta….
0
8
0
0
1
4
RT @RyanGormanDx: Wonderful to see Dr. Lieberman present the results of the @GeneoscopyCo CRC-PREVENT study. Having options for patients ca….
0
2
0
RT @RyanGormanDx: As we wrap up our time at #ACG2023 we leave invigorated with new hopeful knowledge learned and relationships strengthened….
0
2
0
RT @blackingastro: Gratitude and thanks for everyone who joined us at The B.I.G. Event Vancouver! ✨ It was an evening filled with meaningfu….
0
17
0
RT @JAMA_current: In individuals 45 years and older, a multitarget stool RNA test showed high sensitivity for colorectal neoplasia (colorec….
0
6
0
RT @JAMA_current: In individuals 45 years and older, a multitarget stool RNA test showed high sensitivity for colorectal neoplasia (colorec….
0
14
0
RT @GeneoscopyCo: JAMA (@JAMA_current) publishes Geneoscopy’s Pivotal CRC-PREVENT Trial results, reporting highest sensitivity for detectin….
0
2
0
I am officially published in @JAMA_current See results from @GeneoscopyCo's CRC-PREVENT clinical trial for our lead assay in colorectal cancer screening (pending FDA approval):.
jamanetwork.com
This article presents results from a prospective pivotal study in which individuals completed a multitarget stool RNA test prior to undergoing a colonoscopy to determine the sensitivity for detecting...
0
2
10
RT @GeneoscopyCo: Genoscopy In The News: #RNABiomarkers #PMA #FDA #ColonCancerScreening #ClosingTheGap #NonInvasiv….
0
1
0
RT @HealioGastro: In a @GoHealio #GI interview, @EricaBarnell announced favorable results from @GeneoscopyCo's #CRC-PREVENT trial, which as….
0
4
0
RT @obigriffith: I’m really pleased to share this paper from @EricaBarnell et al on Distinct clonal identities of B-ALLs arising after leno….
ashpublications.org
Key Points. B-ALL development in the setting of lenalidomide treatment for MM is a distinct primary malignancy with high incidence of TP53 mutations.Chroni
0
11
0